Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | PTCy based GvHD prophylaxis in myelofibrosis

Tania Jain • 12 Feb 2021
TCT 2021
Myelofibrosis Myeloproliferative Neoplasms Cyclophosphamide

Tania Jain, MBBS, Johns Hopkins University, Baltimore, MD, discusses the results of a retrospective analysis evaluating the outcomes of post-transplantation cyclophosphamide (PTCy) based graft-versus-host disease (GvHD) prophylaxis in patients undergoing allogeneic blood or marrow transplantation for myelofibrosis. Bone marrow transplantation using non-myeloablative conditioning and PTCy for graft-versus-host disease prophylaxis demonstrated comparable clinical outcomes as other studies in myelofibrosis. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Tania Jain

5:11
Haploidentical vs matched donor transplantation in patients with myelofibrosis
Tania Jain • 12 Feb 2021
4:46
SIERRA trial updates: apamistamab in AML
Tania Jain • 12 Feb 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals